Tuesday, 18 Jun 2019

You are here

Preview of EULAR 2019 Abstracts

EULAR 2019 begins today in Madrid and features over 2000 presentations.  After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.  

EULAR will be rolling out many new “guidelines” reports including those addressing rheumatoid arthritis (RA) treatment; immune-related adverse events with checkpoint inhibitors, Sjogrens syndrome and more.

Late-breaking abstracts will be presented on Saturday morning (June 15th) and will include reports on filgotinib (Finch3), secukinumab (FUTURE 5), HLA-DRB1 alleles and responses to Abatacept or Adalimumab, Ultra-low dose rituximab and more.  

Here are some abstracts I’ll be watching (with links to EULAR Abstract site). Which of these interests you?





Two regimens of Rituximab in Scleroderma associated interstitial lung disease

Appears to improve Lung function


KAWAKINRA study: A pilot trial of anakinra in patients with IVIg-resistant Kawasaki disease

Rare disorder with good results in refractory disease. Dosing issues?


Randomized, double blind, placebo controlled trial of Steroids in Hand OA

Looks like it works? But what about adverse effects?


Riociguat in SSc associated ILD

 Anti-fibrotic drug shows some benefit in SSc lung disease



TOLEDEO study – Spacing ABA or TCZ to find the lowest effective dose in RA patients

Looks like less drug therapy carried a high risk of failure


Registry data on long-term outcomes and treatment efficacy in the TRAPS patients

IL-1 inhibitors much more effective than etanercept


Statins reduce relapse rates in Takayasu arteritis

A novel adjunctive therapy?


Fenebrutinib vs. Adalimumab in RA

BTK inhibitor works in MTX- & TNF-IR patients


Implated Vagal nerve stimulator in rheumatoid arthritis

Only 14 patients but novel, and looks effective


Tildrakizumab in active PsA patients

Data on 3rd IL-23 inhibitor


Maxmize Study: Secukinumab on Axial Manifestations in Psoriatic arthritis

Secukinumb works on the Axial outcomes of PsA pts with Spondylitis


 Measures of psoriasis severity and the risk of PsA

Skin severity predicts risk of PsA


 Characterization of psoriatic arthritis and nail psoriasis

 CORRONA - Nail disease predicts worse disease activity


Ultrasound application in Extracranial GCA

 Axillary US correlates with PET findings


EULAR recommendations for the management of irAE

 One of many EULAR recommendations at this meeting


 EULAR Recommendations for the Management of Sjogrens 



The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

EULAR 2019- Day 4 Report

Saturday June 15th was the last half-day at EULAR 2019 but was highlighted by the “late-breaking” (LB) presentations that were presented from the podium and by poster.

Below are the top “LB” presentations from EULAR this year:

Understanding Non-arthritic Rheumatic iRAEs

A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA